Frequently Asked Questions About 600200.SS

Where can I find 600200.SS's financial statements?

JiangSu WuZhong Pharmaceutical Development Co., Ltd. (600200.SS)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.

How much history is available for 600200.SS?

JiangSu WuZhong Pharmaceutical Development Co., Ltd. (600200.SS) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.

How often does 600200.SS update its statements?

JiangSu WuZhong Pharmaceutical Development Co., Ltd. files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

600200.SS (JiangSu WuZhong Pharmaceutical Development Co., Ltd.) is no longer actively trading.

This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.

600200.SS

JiangSu WuZhong Pharmaceutical Development Co., Ltd.

SHH·Biotechnology · Healthcare

¥0.29¥0.03−9.38%

Market cap¥206.16M·Market closed·Dec 29 8:49 AM UTC

CNY · values shown as reported

Line item	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024
Revenue	¥1.87B−11.3%	¥1.78B−5.1%	¥2.03B+14.1%	¥2.24B+10.5%	¥1.60B−28.6%
Cost of revenue	¥1.30B−12.6%	¥1.27B−2.3%	¥1.45B+14.0%	¥1.70B+17.2%	¥829.46M−51.1%
Gross profit	¥571.51M−8.1%	¥505.18M−11.6%	¥578.14M+14.4%	¥542.17M−6.2%	¥769.05M+41.8%
Research & development	¥37.48M+175.6%	¥21.09M−43.7%	¥28.56M+35.4%	¥39.28M+37.5%	¥70.37M+79.2%
General & administrative	¥117.79M−0.1%	¥104.42M−11.4%	¥116.21M+11.3%	¥115.84M−0.3%	¥123.19M+6.3%
Selling & marketing	¥455.78M−5.7%	¥414.51M−9.1%	¥448.31M+8.2%	¥403.37M−10.0%	¥457.88M+13.5%
SG&A (combined)	¥573.57M−4.6%	¥518.93M−9.5%	¥564.51M+8.8%	¥519.21M−8.0%	¥581.06M+11.9%
Other operating expenses	¥441.50M+588.9%	−¥71.35M−116.2%	¥60.20M+184.4%	¥55.84M−7.2%	¥61.34M+9.8%
Total operating expenses	¥1.05B+100.7%	¥468.67M−55.5%	¥653.27M+39.4%	¥614.33M−6.0%	¥712.77M+16.0%
Operating income	−¥481.04M−592.4%	¥36.51M+107.6%	−¥75.14M−305.8%	−¥72.16M+4.0%	¥56.28M+178.0%
Interest income	¥19.96M−34.6%	¥10.95M−45.1%	¥15.96M+45.7%	¥4.07M−74.5%	¥3.64M−10.6%
Interest expense	¥65.27M+24.5%	¥65.14M−0.2%	¥75.86M+16.4%	¥76.34M+0.6%	¥77.39M+1.4%
Other income / (expense), net	−¥23.08M−13.2%	¥2.73M+111.8%	−¥267.21K−109.8%	¥967.17K+462.0%	−¥1.16M−219.5%
Income before tax	−¥504.12M−752.3%	¥39.24M+107.8%	−¥75.40M−292.1%	−¥71.19M+5.6%	¥55.12M+177.4%
Income tax expense	¥3.47M−77.6%	¥18.60M+435.7%	¥2.91M−84.3%	¥3.26M+12.0%	−¥21.84M−769.2%
Net income	−¥506.41M−884.7%	¥22.72M+104.5%	−¥76.27M−435.7%	−¥71.95M+5.7%	¥70.48M+198.0%

EPS (basic)	−¥0.71−888.9%	¥0.03+104.5%	−¥0.11−443.8%	−¥0.10+9.1%	¥0.10+199.0%
EPS (diluted)	−¥0.71−888.9%	¥0.03+104.5%	−¥0.11−443.8%	−¥0.10+9.1%	¥0.10+199.0%
Weighted avg shares (basic)	713,254,536	709,883,812	712,791,719	712,328,831	711,954,313
Weighted avg shares (diluted)	713,254,536	709,883,812	712,791,719	712,328,831	711,954,313

Depreciation & amortization	¥83.44M−3.6%	¥48.75M−41.6%	¥46.67M−4.3%	¥44.90M−3.8%	¥46.89M+4.4%
EBITDA	−¥355.42M−264.7%	¥152.66M+143.0%	¥47.13M−69.1%	¥50.06M+6.2%	¥179.40M+258.4%

Frequently Asked Questions About 600200.SS

Where can I find 600200.SS's financial statements?: JiangSu WuZhong Pharmaceutical Development Co., Ltd. (600200.SS)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.
How much history is available for 600200.SS?: JiangSu WuZhong Pharmaceutical Development Co., Ltd. (600200.SS) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.
How often does 600200.SS update its statements?: JiangSu WuZhong Pharmaceutical Development Co., Ltd. files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

Line item

FY 2020

FY 2021

FY 2022

FY 2023

FY 2024

Trend

Revenue

¥1.87B−11.3%

¥1.78B−5.1%

¥2.03B+14.1%

¥2.24B+10.5%

¥1.60B−28.6%

Cost of revenue

¥1.30B−12.6%

¥1.27B−2.3%

¥1.45B+14.0%

¥1.70B+17.2%

¥829.46M−51.1%

Gross profit

¥571.51M−8.1%

¥505.18M−11.6%

¥578.14M+14.4%

¥542.17M−6.2%

¥769.05M+41.8%

Research & development

¥37.48M+175.6%

¥21.09M−43.7%

¥28.56M+35.4%

¥39.28M+37.5%

¥70.37M+79.2%

General & administrative

¥117.79M−0.1%

¥104.42M−11.4%

¥116.21M+11.3%

¥115.84M−0.3%

¥123.19M+6.3%

Selling & marketing

¥455.78M−5.7%

¥414.51M−9.1%

¥448.31M+8.2%

¥403.37M−10.0%

¥457.88M+13.5%

SG&A (combined)

¥573.57M−4.6%

¥518.93M−9.5%

¥564.51M+8.8%

¥519.21M−8.0%

¥581.06M+11.9%

Other operating expenses

¥441.50M+588.9%

−¥71.35M−116.2%

¥60.20M+184.4%

¥55.84M−7.2%

¥61.34M+9.8%

Total operating expenses

¥1.05B+100.7%

¥468.67M−55.5%

¥653.27M+39.4%

¥614.33M−6.0%

¥712.77M+16.0%

Operating income

−¥481.04M−592.4%

¥36.51M+107.6%

−¥75.14M−305.8%

−¥72.16M+4.0%

¥56.28M+178.0%

Interest income

¥19.96M−34.6%

¥10.95M−45.1%

¥15.96M+45.7%

¥4.07M−74.5%

¥3.64M−10.6%

Interest expense

¥65.27M+24.5%

¥65.14M−0.2%

¥75.86M+16.4%

¥76.34M+0.6%

¥77.39M+1.4%

Other income / (expense), net

−¥23.08M−13.2%

¥2.73M+111.8%

−¥267.21K−109.8%

¥967.17K+462.0%

−¥1.16M−219.5%

Income before tax

−¥504.12M−752.3%

¥39.24M+107.8%

−¥75.40M−292.1%

−¥71.19M+5.6%

¥55.12M+177.4%

Income tax expense

¥3.47M−77.6%

¥18.60M+435.7%

¥2.91M−84.3%

¥3.26M+12.0%

−¥21.84M−769.2%

Net income

−¥506.41M−884.7%

¥22.72M+104.5%

−¥76.27M−435.7%

−¥71.95M+5.7%

¥70.48M+198.0%

EPS (basic)

−¥0.71−888.9%

¥0.03+104.5%

−¥0.11−443.8%

−¥0.10+9.1%

¥0.10+199.0%

EPS (diluted)

−¥0.71−888.9%

¥0.03+104.5%

−¥0.11−443.8%

−¥0.10+9.1%

¥0.10+199.0%

Weighted avg shares (basic)

713,254,536

709,883,812

712,791,719

712,328,831

711,954,313

Weighted avg shares (diluted)

713,254,536

709,883,812

712,791,719

712,328,831

711,954,313

Depreciation & amortization

¥83.44M−3.6%

¥48.75M−41.6%

¥46.67M−4.3%

¥44.90M−3.8%

¥46.89M+4.4%

EBITDA

−¥355.42M−264.7%

¥152.66M+143.0%

¥47.13M−69.1%

¥50.06M+6.2%

¥179.40M+258.4%